Eli Lilly and Co (XSWX:LLY) Other Gross PPE: CHF33,882 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:LLY Eli Lilly and Co XSWX:LLY
93 GF Score
Price CHF955.00
GF Value CHF1,220.12
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co Other Gross PPE?

Eli Lilly and Co XSWX:LLY 93 Other Gross PPE is CHF33,882 Mil as of Jun. 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 93/100 and a GF Value™ of CHF1,220.12 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Eli Lilly and Co's Other Gross PPE for the quarter that ended in Jun. 2026 was CHF33,882 Mil.

Eli Lilly and Co's quarterly Other Gross PPE increased from Dec. 2025 (CHF10,747 Mil) to Mar. 2026 (CHF20,895 Mil) and increased from Mar. 2026 (CHF20,895 Mil) to Jun. 2026 (CHF33,882 Mil).

Eli Lilly and Co's annual Other Gross PPE increased from Dec. 2023 (CHF8,933 Mil) to Dec. 2024 (CHF10,216 Mil) and increased from Dec. 2024 (CHF10,216 Mil) to Dec. 2025 (CHF10,747 Mil).

Eli Lilly and Co Other Gross PPE Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Other Gross PPE Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,231.16 8,762.91 8,932.52 10,215.95 10,746.99

Eli Lilly and Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26,903.67 27,646.09 10,746.99 20,894.94 33,881.53
XSWX:LLY
93GF Score
Eli Lilly and Co XSWX:LLY
Other Gross PPE is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of CHF33,882 Mil mean?
Eli Lilly and Co (XSWX:LLY) has a Other Gross PPE of CHF33,882 Mil as of Jun. 2026. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Other Gross PPE too high?
Eli Lilly and Co's current Other Gross PPE is CHF33,882 Mil. Overall, Eli Lilly and Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Other Gross PPE compare to JNJ and ABBV?
Eli Lilly and Co's Other Gross PPE of CHF33,882 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Drug Manufacturers company?
A good Other Gross PPE depends on the Drug Manufacturers industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Other Gross PPE is CHF33,882 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,220.12, compared to a current price of CHF955.00 — trading 21.7% below its estimated fair value. The current Other Gross PPE is CHF33,882 Mil. Eli Lilly and Co's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Other Gross PPE is CHF33,882 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF955.00 is trading 21.7% below its estimated GF Value™ of CHF1,220.12. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Other Gross PPE: CHF33,882 Mil
  • GF Value™: CHF1,220.12 vs. price of CHF955.00 (21.7% below fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
93GF Score

Get the complete analysis for XSWX:LLY

Other Gross PPE is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF955.00
Price
CHF1,220.12
GF Value